26 MAIN STREET, SUITE 101, CHATHAM, NJ
Other Events
Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Promotes Thomas Englese, MBA, to Chief Commercial Officer
Material disclosure
Reports Second Quarter 2026 Financial Results and Operational Highlights
Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Dr. Gregory M. Sullivan Retirement as Chief Medical Officer
Announces Major Managed Medicare Payer Agreement for TONMYA®
Q2
Q1
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload